Patient-Reported Outcomes Including Fatigue in Primary Sjögren's Syndrome

Rheumatic Disease Clinics of North America

Volumn 34, Issue 4, 2008, Pages 949-962

  Bowman, Simon J ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical trials; Fatigue; Outcome; Sj gren's

Indexed keywords

ALPHA INTERFERON; CEVIMELINE; CYCLOSPORIN; CYTOKINE; EPRATUZIMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; MONOCLONAL ANTIBODY; PILOCARPINE; PLACEBO; PRASTERONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG;

ARTHRALGIA; BIOLOGICAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRY EYE; DRY NOSE; DRY SKIN; FIBROMYALGIA; HUMAN; INFLAMMATION; MUSCLE FATIGUE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RAYNAUD PHENOMENON; REVIEW; SJOEGREN SYNDROME; STEROID THERAPY; VAGINAL DRYNESS; XEROSTOMIA;

ACTIVITIES OF DAILY LIVING; CLINICAL TRIALS AS TOPIC; FATIGUE; HEALTH STATUS INDICATORS; HUMANS; KERATOCONJUNCTIVITIS SICCA; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; QUESTIONNAIRES; SJOGREN'S SYNDROME; XEROSTOMIA;

EID: 54549122451     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2008.08.010     Document Type: Review

References (62)

1. Jonsson R., Bowman S.J., and Gordon T.P. Sjögren's syndrome. In: Koopman W.J., and Moreland L.W. (Eds). Arthritis and Allied Conditions. 15th edition (2005), Lippincott Williams & Wilkins, Philadelphia 1681-1705 Chapter 78
2. Bowman S.J., Booth D.A., Platts R.G., and UK Sjögren's Interest Group. Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool. Rheumatology 43 (2004) 758-764
3. Barendregt P.J., Visser M.R., Smets E.M., et al. Fatigue in primary Sjögren's syndrome. Ann Rheum Dis 57 (1998) 291-295
4. Strömbeck B., Ekdahl C., Manthorpe R., et al. Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 29 (2000) 20-28
5. Bowman S.J., Sutcliffe N., Isenberg D.A., et al. Sjögren's Systemic Clinical Activity Index (SCAI): a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. Rheumatology 46 12 (2007) 1845-1851
6. Skopouli F.N., Dafni U., and Ioannidis J.P.A. Clinical evolution and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 29 (2000) 296-304
7. Pertovaara M., Pukkala E., Laippala P., et al. A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60 (2001) 467-472
8. Davidson B.K., Kelly C.A., and Griffiths I.D. Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology 38 (1999) 245-253
9. Bates D.W., Schmitt W., Buchwald D., et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 153 24 (1993) 2759-2765
10. Wessely S., Hotopf M., and Sharpe M. Chronic fatigue and its syndromes (1998), Oxford University Press, Oxford
11. Hartkamp A., Geenen R., Bijl M., et al. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjogren's syndrome. Ann Rheum Dis 63 (2004) 1335-1337
12. Bax H.I., Vriesendorp T.M., Kallenberg C.G.M., et al. Fatigue and immune activity in Sjogren's syndrome. Ann Rheum Dis 61 (2002) 284
13. Valtysdottir S.T., Gudbjornsson B., Lindqvist U., et al. Anxiety and depression in patients with primary Sjogren's syndrome. J Rheumatol 27 (2000) 165-169
14. Huyser B.A., Parker J.C., Thoreson R., et al. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 41 12 (1998) 2230-2237
15. Giles I., and Isenberg D. Fatigue in primary Sjögren's syndrome: Is there a link with the fibromyalgia syndrome?. Ann Rheum Dis 59 11 (2000) 875-878
16. Andersson S.I., Manthorpe R., and Theander E. Situational patterns in coping with primary Sjögren's syndrome. Psychol Health Med 6 1 (2001) 29-40
17. Yellen S.B., Cella D.F., Webster K., et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13 (1997) 63-74
18. Krupp L.B., LaRocca N.G., Muir-Nash J., et al. The fatigue severity scale. Arch Neurol 46 (1989) 1121-1123
19. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analogue scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 31 (2004) 1896-1902
20. Dass S., Bowman S.J., Vital E.M., et al. Reduction of fatigue in Sjögren's syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis (2008) [Epub ahead of print]
21. Smets E.M., Garssen B., Bonke B., et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39 (1995) 315-325
22. Schwartz J.E., Jandorf L., and Krupp L.B. The measurement of fatigue: a new instrument. J Psychosom Res 37 (1993) 753-762
23. Piper B.F., Dibble S.L., Dodd M.J., et al. The revised Piper fatigue scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25 4 (1998) 677-684
24. Chalder T., Berelowitz G., Pawlikowska T., et al. Development of a fatigue scale. J Psychosom Res 37 (1993) 147-153
25. Wells G., Li T., Maxwell L., et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 67 (2008) 260-265
26. Ware J.E., Snow K.K., Kosinski M., et al. SF-36 Health Survey. Manual and interpretation guide (1993), The Health Institute, New England Medical Center, Boston
27. Goodchild C.E., Treharne G.J., Booth D.A., et al. Measuring fatigue among women with Sjögren's syndrome or rheumatoid arthritis: a comparison of the Profile of Fatigue (ProF) and the Multidimensional Fatigue Inventory (MFI). Musculoskeletal Care (Dec 17, 2007) [Epub ahead of print]
28. Lwin-T C.T., Bishay M., Platts R.G., et al. The assessment of fatigue in primary Sjögren's syndrome. Scand J Rheumatol 32 (2003) 1-5
29. Strombeck B., Theander E., and Jacobsson L.T. Assessment of fatigue in primary Sjogren's syndrome: the Swedish version of the profile of fatigue. Scand J Rheumatol 34 (2005) 455-459
30. Fox R.I., Dixon R., Guarrasi V., et al. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5 Suppl 1 (1996) S31-S36
31. Kruize A.A., Hene R.J., Kallenberg C.G., et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 52 (1993) 360-364
32. Mariette X., Ravaud P., Steinfeld S., et al. Inefficacy of infliximab in primary Sjögren's syndrome. Arthritis Rheum 50 (2004) 1270-1276
33. Hartkamp A., Geenen R., Godaert G.L., et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren's syndrome: a randomised controlled trial. Ann Rheum Dis 67 1 (2008) 91-97
34. Strombeck B.E., Theander E., and Jacobsson L.T.H. Effects of exercise on aerobic capacity and fatigue in women with primary Sjögren's syndrome. Rheumatology 46 (2007) 868-871
35. Devauchelle-Pensec V., Pennec Y., Morvan J., et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Care Res 57 (2007) 310-317
36. Pijpe J., van Imhoff G.W., Spijkervet F.K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52 (2005) 2740-2750
37. Seror R., Sordet C., Guillevin L., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 66 (2007) 351-357
38. Levesque M.C., Prak N.L., St Clair E.W., et al. Longitudinal analysis of lymphocyte subsets in patients with primary Sjogren's syndrome (pSS) treated with rituximab: results from an open-label clinical trial. Arthritis Rheum 56 9 Suppl (2007) S445
39. Steinfeld S.D., Tant L., Burmester G., et al. Epratuzimab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65 (2006) 796-803
40. Wolfe F., and Michaud K. Fatigue, rheumatoid arthritis, anti-tumour necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol 31 (2004) 2115-2120
41. McMonnies C.W. Key questions in a dry eye history. J Am Optom Assoc 57 (1986) 512-517
42. Vitali C., Bombardieri S., Jonsson R., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 (2002) 554-558
43. Fox P.C., Busch K.A., and Baum B.J. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 115 (1987) 581-584
44. Pai S., Ghezzi E.M., and Ship J.A. Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91 (2001) 311-316
45. Henson B.S., Inglehart M.R., Eisbruch A., et al. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 37 (2001) 84-93
46. Slade G.D., and Spencer A.J. Development and evaluation of the Oral Health Impact Profile. Community Dent Health 11 (1994) 3-11
47. Thomson W.M., Chalmers J.M., Spencer A.J., et al. The Xerostomia Inventory: a multi-item approach to measuring dry mouth. Community Dent Health 16 (1999) 12-17
48. Field E.A., Rostron J.L., Longman L.P., et al. The development and initial validation of the Liverpool Sicca index to assess symptoms and dysfunction in patients with primary Sjogren's syndrome. J Oral Pathol Med 32 (2003) 154-162
49. Bowman S.J., Booth D.A., Platts R.G., et al., UK Sjögren's Interest Group. Validation of the Sicca Symptoms Inventory (SSI) for clinical studies of Sjögren's syndrome. J Rheumatol 30 (2003) 1259-1266
50. Vivino F.B., Al-Hashimi I., Khan Z., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren's syndrome. Arch Intern Med 159 (1999) 174-181
51. Schiffman R.M., Christianson M.D., Jacobsen G., et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 118 (2000) 615-621
52. Vitale S., Goodman L.A., Reed G.F., et al. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye. Health Qual Life Outcomes 2 (2004) 44
53. Hay E.M., Thomas E., Pal B., et al. Weak association between subjective symptoms of and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis 57 (1998) 20-24
54. Fife R.S., Chase W.F., Dore R.K., et al. Cevimeline for the treatment of xerostomia in patients with Sjögren's syndrome. A randomized trial. Arch Intern Med 162 (2002) 1293-1300
55. Petrone D., Condemi J.J., Fife R., et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46 3 (2002) 748-754
56. Shiozawa S., Tanaka Y., and Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-a for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 18 (1998) 255-262
57. Cummins M.J., Papas A., Kammer G.M., et al. Treatment of primary Sjogren's syndrome with low-dose human interferon α administered by the oromucosal route: combined phase III results. Arthritis Rheum 49 (2003) 585-593
58. Stevenson D., Tauber J., Reis B.L., and The Cyclosporin A Phase 2 Study Group. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomised trial. Ophthalmology 107 (2000) 967-974
59. Sall K., Stevenson O.D., Mundorf T.K., et al., CsA Phase 3 Study Group. Two multicenter, randomised studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 107 (2000) 631-639
60. Bowman S., Pillemer S., Jonsson R., et al. Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology 40 (2001) 1180-1188
61. Pillemer S.R., Smith J., Fox P.C., et al. Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, U S A. J Rheumatol 32 (2005) 143-149
62. Vitali C., Palombi G., Baldini C., et al. Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 56 7 (2007) 2223-2231